n(6)-carboxymethyllysine has been researched along with Chronic Kidney Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergero, D; Borghi, R; Bovero, A; Bruni, N; Monacelli, F; Nery, J; Odetti, P; Prola, L; Schiavone, A; Traverso, N; Valle, E; Vergnano, D | 1 |
| Cai, W; He, JC; Li, Z; Linden, E; Uribarri, J; Vlassara, H; Winston, J; Xue, C | 1 |
2 other study(ies) available for n(6)-carboxymethyllysine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Investigation of hallmarks of carbonyl stress and formation of end products in feline chronic kidney disease as markers of uraemic toxins.
Topics: Advanced Oxidation Protein Products; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Biomarkers; Cats; Lysine; Oxidative Stress; Renal Insufficiency, Chronic; Urea | 2019 |
Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation.
Topics: Adult; Aged; Case-Control Studies; Cells, Cultured; Cross-Sectional Studies; Endothelial Cells; Endothelium, Vascular; Female; Glomerular Filtration Rate; Glycation End Products, Advanced; Humans; Hyperemia; Lysine; Male; Middle Aged; Nitric Oxide Synthase Type III; Pyruvaldehyde; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Regional Blood Flow; Renal Insufficiency, Chronic; RNA Interference; RNA, Messenger; RNA, Small Interfering; Severity of Illness Index; Skin; Up-Regulation | 2008 |